PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19451133-0	2009	Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp.	Tigecycline	40-51	histocompatibility minor 13	Homo sapiens	130-133	
30587490-8	2018	Although collistin showed 0% resistant while ceftriaxone, ciprofloxacin, gentamicin, and tigecycline showed 90%, 68%, 66%, 66% and 62% resistance against Acinetobacter spp.	Tigecycline	89-100	histocompatibility minor 13	Homo sapiens	168-171	
20031463-0	2010	The susceptibility to tigecycline of Acinetobacter spp.	Tigecycline	22-33	histocompatibility minor 13	Homo sapiens	51-54	
20045291-0	2010	Activity of tigecycline against multidrug-resistant clinical isolates of Clostridium spp.	Tigecycline	12-23	histocompatibility minor 13	Homo sapiens	85-88	
20551633-14	2010	CONCLUSIONS: Tigecycline breakpoints for Acinetobacter spp.	Tigecycline	13-24	histocompatibility minor 13	Homo sapiens	55-58	
21482488-10	2011	This relatively high prevalence of tigecycline and colistin-resistant isolates indicates an emerging therapeutic problem which may severely compromise the treatment of MDR Acinetobacter spp.	Tigecycline	35-46	histocompatibility minor 13	Homo sapiens	186-189	
20727474-0	2010	In vitro activity of tigecycline and comparators on Acinetobacter spp.	Tigecycline	21-32	histocompatibility minor 13	Homo sapiens	66-69	
19451133-1	2009	OBJECTIVES: To compare the tigecycline activity profile against Acinetobacter spp.	Tigecycline	27-38	histocompatibility minor 13	Homo sapiens	78-81	
18782779-0	2008	Susceptibility testing of tigecycline against Acinetobacter spp.	Tigecycline	26-37	histocompatibility minor 13	Homo sapiens	60-63	
19297274-7	2009	Our results suggest that tigecycline may be an acceptable alternative for therapy in patients with VAP caused by MDR-Acinetobacter spp.	Tigecycline	25-36	histocompatibility minor 13	Homo sapiens	131-134	
16105565-14	2005	Tigecycline was also active against Acinetobacter spp.	Tigecycline	0-11	histocompatibility minor 13	Homo sapiens	50-53	
18567913-0	2008	Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp.	Tigecycline	44-55	histocompatibility minor 13	Homo sapiens	104-107	
17548459-0	2007	Tigecycline disk diffusion breakpoints of Acinetobacter spp.	Tigecycline	0-11	histocompatibility minor 13	Homo sapiens	56-59	
18689874-0	2008	Comment on: Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp.	Tigecycline	56-67	histocompatibility minor 13	Homo sapiens	116-119	
18614749-2	2008	Tigecycline has in vitro activity against Acinetobacter spp.	Tigecycline	0-11	histocompatibility minor 13	Homo sapiens	56-59	
18614749-4	2008	OBJECTIVE: To describe the clinical and microbiologic outcomes of patients who received tigecycline for the treatment of infections caused by Acinetobacter spp.	Tigecycline	88-99	histocompatibility minor 13	Homo sapiens	156-159	
17462865-0	2007	In vitro antibacterial activity of tigecycline in comparison with doxycycline, ciprofloxacin and rifampicin against Brucella spp.	Tigecycline	35-46	histocompatibility minor 13	Homo sapiens	125-128